GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

How will the Trump administration's cuts to HIV research impact the progress that's been made towards ending the epidemic in the U.S.?

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the. The company announced that the US FDA approved Yeztugo ® (lenacapavir), ...

The Food and Drug Administration (FDA) recently approved lenacapavir for HIV prevention in both men and women. Many experts believe this twice a year treatment could be a game changer in the fight ...

The Australian researchers developed a novel mRNA-based technology capable of reaching the white blood cells where HIV lies ...

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But ...

Lenacapavir has demonstrated enormous potential as a new HIV prevention tool with a 100 per cent efficacy rate and zero ...

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc.